PHASE 1B TRIAL OF MONALIZUMAB (NKG2A INHIBITOR) PLUS DURVALUMAB: SAFETY AND EFFICACY IN PATIENTS WITH METASTATIC OVARIAN, CERVICAL, AND MICROSATELLITE-STABLE ENDOMETRIAL CANCERS

被引：2
|
作者：
Banerjee, Susana [1 ,2 ]
Oaknin, Ana [3 ]
Sanchez-Simon, Inmaculada [4 ]
Salgado, Alfonso Cortes [5 ]
Patel, Sandip Pravin [6 ]
Oza, Amit [7 ]
Das, Mayukh [8 ]
Kourtesis, Panagiotis [8 ]
Ascierto, Maria Libera [8 ]
Diamond, Jennifer R. [9 ]
机构：
[1] Royal Marsden NHS Fdn Trust, London, England
[2] Inst Canc Res, London, England
[3] Hosp Valle De Hebron, Vall Dhebron Inst Oncol Vhio, Barcelona, Spain
[4] Hosp Univ Virgen, Granada, Spain
[5] Hosp Univ Ramon, Madrid, Spain
[6] Ucsd Moore Canc Ctr, La Jolla, CA USA
[7] Princess Margaret Canc Ctr, Toronto, ON, Canada
[8] Astrazeneca, Cambridge, England
[9] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA
来源：
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER | 2020年 / 30卷
关键词：
D O I：
10.1136/ijgc-2020-ESGO.147
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
518
引用
收藏
页码：A86 / A87
页数：2
相关论文
共 50 条
  • [21] ANALYSIS OF EFFICACY AND SAFETY OF OLARATUMAB plus DOXORUBICIN OR DOXORUBICIN ALONE IN PATIENTS WITH UTERINE LEIOMYOSARCOMA: RETROSPECTIVE ASSESSMENT OF THE PHASE 1B/2 STUDY JGDG
    Van Tine, B. A.
    Peterson, P.
    Shahir, A.
    Ilaria, R., Jr.
    Jones, R. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 1368 - 1368
  • [22] ANALYSIS OF EFFICACY AND SAFETY OF OLARATUMAB plus DOXORUBICIN OR DOXORUBICIN ALONE IN PATIENTS WITH UTERINE LEIOMYOSARCOMA: RETROSPECTIVE ASSESSMENT OF THE PHASE 1B/2 STUDY JGDG
    Van Tine, B. A.
    Peterson, P.
    Shahir, A.
    Ilaria, R., Jr.
    Jones, R. L.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2017, 27 : 490 - 490
  • [23] An analysis of efficacy and safety of olaratumab plus doxorubicin or doxorubicin alone in patients with uterine leiomyosarcoma: A retrospective assessment of the phase 1b/2 study JGDG
    Van Tine, B. A.
    Peterson, P. M.
    Shahir, A.
    Ilaria, R.
    Jones, R. L.
    GYNECOLOGIC ONCOLOGY, 2017, 145 : 93 - 93
  • [24] EFFICACY AND SAFETY OF GX-I7 PLUS PEMBROLIZUMAB FOR HEAVILY PRETREATED PATIENTS WITH METASTATIC TRIPLE NEGATIVE BREAST CANCER: THE PHASE 1B/2 KEYNOTE-899 STUDY
    Sohn, Joo
    Im, Young Hyuk
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A197 - A198
  • [25] A phase 1b/2 trial of PXS-5505 combined with first line atezolizumab plus bevacizumab for treating patients with unresectable or metastatic hepatocellular carcinoma
    Burchard, Paul R.
    Ruffolo, Luis I.
    Ullman, Nicholas
    Dave, Yatee
    Belt, Brian A.
    Linehan, David C.
    Hernandez-Alejandro, Roberto
    Badri, Nabeel
    CLINICAL CANCER RESEARCH, 2022, 28 (17)
  • [26] Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+breast cancer (TBCRC 050).
    Stringer-Reasor, Erica Michelle
    Li, Yufeng
    Witherspoon, Felicia
    Specht, Jennifer M.
    Mesias, Jesus Del Santo Anampa
    Nanda, Rita
    Dees, Elizabeth Claire
    Wolff, Antonio C.
    Krop, Ian E.
    Lin, Nancy U.
    Rimawi, Mothaffar F.
    Yang, Eddy Shih-Hsin
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [27] Efficacy and safety of mitazalimab in combination with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC): An interim analysis of the optimize-1 phase 1b/2 study
    Prenen, Hans
    Borbath, Ivan
    Paula Geboes, Karen
    Alexandre Cassier, Philippe
    Lambert, Aurelien
    Mitry, Emmanuel
    Macarulla, Teresa
    Taieb, Julien
    Blanc, Jean-Frederic
    Feliu Batlle, Jaime
    Rodriguez Garrote, Mercedes
    Pazo Cid, Roberto A.
    Valladares-Ayerbes, Manuel
    Nordbladh, Karin
    Enell Smith, Karin
    Ellmark, Peter
    Carlsson, Malin
    Pico de Coana, Yago
    Vijay Ambarkhane, Sumeet
    Van Laethem, Jean-Luc
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [28] A phase 1b study of the CDK4/6 inhibitor ribociclib in combination with the PD-1 inhibitor spartalizumab in patients with hormone receptor-positive metastatic breast cancer (HR plus MBC) and metastatic ovarian cancer (MOC)
    Herold, Christina I.
    Trippa, Lorenzo
    Li, Tianyu
    Khanh Do
    Bardia, Aditya
    Anderson, Leilani
    Montazeri, Kamaneh
    Pittenger, Jessica
    Andrews, Chelsea
    Mittendorf, Elizabeth A.
    Goel, Shorn
    Winer, Eric P.
    Shapiro, Geoffrey I.
    Tolaney, Sara M.
    CANCER RESEARCH, 2020, 80 (04)
  • [29] Results of the safety and tolerability of ivaltinostat plus capecitabine in the phase 1b portion of a phase 1b/2, dose-escalation, randomized, multi-center study in the maintenance (maint) setting in patients with metastatic pancreatic adenocarcinoma (mPDAC).
    Walker, Evan Justin
    Fountzilas, Christos
    Borazanci, Erkut Hasan
    Shields, Anthony F.
    D'Olimpio, James Thomas
    Hecht, J. Randolph
    Tang, Shou-Ching
    Michelson, Glenn
    Liganor, Lorna
    Cho, Sangsook Ahn
    Ko, Andrew H.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (3_SUPPL) : 666 - 666
  • [30] Design of a phase 1b/2 study to evaluate the efficacy and safety of eribulin mesylate in combination with pembrolizumab in patients with metastatic triple-negative breast cancer
    Berrak, E.
    Atkan, G.
    Song, J.
    Almonte, A.
    Karantza, V.
    Yuan, R.
    CANCER RESEARCH, 2016, 76
12345